<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00021073</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02389</org_study_id>
    <secondary_id>NCI-2012-02389</secondary_id>
    <secondary_id>CDR0000068745</secondary_id>
    <secondary_id>MAYO-MC0014</secondary_id>
    <secondary_id>NCI-2450</secondary_id>
    <secondary_id>MC0014</secondary_id>
    <secondary_id>2450</secondary_id>
    <nct_id>NCT00021073</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Advanced Cancer</brief_title>
  <official_title>Phase I Study of Flavopiridol in Combination With 5-Fluorouracil, Leucovorin and Irinotecan in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of combining flavopiridol, fluorouracil, and&#xD;
      leucovorin with or without irinotecan in treating patients who have advanced cancer. Drugs&#xD;
      used in chemotherapy use different ways to stop tumor cells from dividing so they stop&#xD;
      growing or die. Combining more than one drug may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of flavopiridol, fluorouracil, and leucovorin calcium&#xD;
      with or without irinotecan in patients with advanced malignancy.&#xD;
&#xD;
      II. Assess the toxic effects of these regimens in these patients. III. Determine the clinical&#xD;
      response in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This a dose-escalation study of flavopiridol (FLAVO), fluorouracil (5-FU), and&#xD;
      irinotecan. Patients are assigned to 1 of 2 groups. Groups I and II are conducted&#xD;
      sequentially.&#xD;
&#xD;
      Group I: Patients receive FLAVO IV over 24 hours on day 1 and leucovorin calcium (CF) IV and&#xD;
      5-FU IV over 1.5 hours daily on days 2-5. Courses repeat every 3 weeks in the absence of&#xD;
      disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating&#xD;
      doses of FLAVO and 5-FU until the maximum tolerated doses (MTD) are determined. The MTD is&#xD;
      defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting&#xD;
      toxicity.&#xD;
&#xD;
      Group II: Once the MTDs for FLAVO and 5-FU are determined, patients receive FLAVO, CF, and&#xD;
      5-FU as in group I plus irinotecan IV over 1.5 hours on day 1. Courses repeat as in group I.&#xD;
      Cohorts of 3-6 patients receive escalating doses of irinotecan until the MTD is determined.&#xD;
      The MTD is defined as in group I.&#xD;
&#xD;
      Patients are followed at 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 57-90 patients will be accrued for this study within 18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of toxicity incidents of alvocidib, 5-fluorouracil, leucovorin calcium with and without irinotecan hydrochloride, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of responses (complete response, partial response, stable disease, and progressive disease) assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Summarized by simple descriptive summary statistics.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (alvocidib, combination chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group I: Patients receive FLAVO IV over 24 hours on day 1 and CF IV and 5-FU IV over 1.5 hours daily on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of FLAVO and 5-FU until the MTD are determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.&#xD;
Once the MTDs for FLAVO and 5-FU are determined, patients receive FLAVO, CF, and 5-FU as in group I plus irinotecan IV over 1.5 hours on day 1. Courses repeat as in group I. Cohorts of 3-6 patients receive escalating doses of irinotecan until the MTD is determined. The MTD is defined as in group I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alvocidib, combination chemotherapy)</arm_group_label>
    <other_name>FLAVO</other_name>
    <other_name>flavopiridol</other_name>
    <other_name>HMR 1275</other_name>
    <other_name>L-868275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alvocidib, combination chemotherapy)</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alvocidib, combination chemotherapy)</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (alvocidib, combination chemotherapy)</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
    <other_name>irinotecan</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignancy&#xD;
&#xD;
               -  Unresectable tumor&#xD;
&#xD;
               -  No known standard therapy with curative potential or capability of extending life&#xD;
                  expectancy&#xD;
&#xD;
          -  No untreated CNS metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL&#xD;
&#xD;
          -  Direct bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 3 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No baseline diarrhea, defined as at least 4 loose or liquid stools/day&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             fully recovered from acute reversible effects&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No other concurrent ancillary investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Bible</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

